{"id":78347,"date":"2026-05-09T03:04:28","date_gmt":"2026-05-09T03:04:28","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/78347\/"},"modified":"2026-05-09T03:04:28","modified_gmt":"2026-05-09T03:04:28","slug":"novo-nordisk-guidance-lift-tests-valuation-as-oral-wegovy-demand-surges-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/78347\/","title":{"rendered":"Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S.<\/p>\n

Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format.<\/p>\n

The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market.<\/p>\n

Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a fresh angle to the investment case. The stock is up 13.6% over the past week and 24.8% over the past month, although it shows a 12.7% decline year to date and a 30.0% decline over the past year. Over 5 years, the stock has a 26.5% return, which gives longer term holders a different experience than recent entrants.<\/p>\n

For investors watching NYSE:NVO, the raised guidance and rapid prescription uptake highlight how important execution in both drug development and commercialization can be. The weight loss market remains highly competitive, so it may be useful to track how oral Wegovy adoption, pricing decisions, and any further guidance updates affect the company story over the coming quarters.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"NYSE:NVO<\/a> NYSE:NVO Earnings & Revenue Growth as at May 2026 <\/p>\n

We’ve flagged 4 risks for Novo Nordisk. See which could impact your investment.<\/a><\/p>\n

Quick Assessment <\/p>\n

\u2696\ufe0f Price vs Analyst Target: At US$45.76, the stock trades about 4% below the US$47.66 analyst target, which is within a relatively tight range.<\/p>\n

\u2705 Simply Wall St Valuation: The shares are described as trading 57.8% below an estimated fair value, which flags a significant valuation gap in that model.<\/p>\n

\u2705 Recent Momentum: A 30 day return of roughly 24.8% shows strong short term momentum following the oral Wegovy launch and guidance upgrade.<\/p>\n

There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value<\/a>.<\/p>\n

Key Considerations <\/p>\n

\ud83d\udcca Raised guidance and rapid oral Wegovy uptake put more attention on how much of current pricing already reflects weight loss drug expectations.<\/p>\n

\ud83d\udcca Keep an eye on prescription trends, pricing decisions versus Eli Lilly and any updates to revenue or earnings guidance tied to oral formulations.<\/p>\n

\u26a0\ufe0f Forecast earnings declining by an average of 0.5% per year over the next 3 years and a high level of debt are important offsets to the current excitement.<\/p>\n

Dig Deeper <\/p>\n

For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis<\/a>. Alternatively, you can visit the community page for Novo Nordisk<\/a> to see how other investors believe this latest news will impact the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NVO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":69813,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[276,272,3020,280,3388],"class_list":{"0":"post-78347","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-eli-lilly","9":"tag-novo-nordisk","10":"tag-stock-portfolio","11":"tag-weight-loss","12":"tag-weight-loss-drug"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116542404419370350","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/78347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=78347"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/78347\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/69813"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=78347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=78347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=78347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}